SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]
SEC Accession No. 0001213900-22-051844
Filing Date
2022-08-29
Accepted
2022-08-29 16:51:05
Documents
33
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 6-K ea165093-6ka1_biondvax.htm   iXBRL 6-K/A 15220
2 PRESS RELEASE DATED AUGUST 25, 2022 ea165093ex99-1_biondvax.htm EX-99.1 96868
3 UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 202 ea165093ex99-2_biondvax.htm   iXBRL EX-99.2 374478
9 GRAPHIC ex99-1_001.jpg GRAPHIC 12672
  Complete submission text file 0001213900-22-051844.txt   1654565

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE bvxv-20220630.xsd EX-101.SCH 32081
5 XBRL CALCULATION FILE bvxv-20220630_cal.xml EX-101.CAL 24542
6 XBRL DEFINITION FILE bvxv-20220630_def.xml EX-101.DEF 68135
7 XBRL LABEL FILE bvxv-20220630_lab.xml EX-101.LAB 196076
8 XBRL PRESENTATION FILE bvxv-20220630_pre.xml EX-101.PRE 74752
27 EXTRACTED XBRL INSTANCE DOCUMENT ea165093-6ka1_biondvax_htm.xml XML 120281
Mailing Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000
Business Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000 972-8-9302529
BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K/A | Act: 34 | File No.: 001-37353 | Film No.: 221211785
SIC: 2836 Biological Products, (No Diagnostic Substances)